ArticleJournal of traditional and complementary medicine2025
Treatment of allergic rhinitis with a mixed Chinese herbal formula via regulatory B cells: A prospective pilot study.
Article in Journal of traditional and complementary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Mixed Chinese herbal formulas (CHFs) are commonly prescribed for allergic rhinitis (AR), but few studies explore their mechanisms. Prior research highlighted the immunomodulatory effects of a specific mixed CHF (Xin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang) in perennial AR by targeting neutrophils, dendritic cells, and CD4 Experimental procedure: In this 3-month prospective pilot study, we assessed the immunomodulatory effect of a mixed CHF on patients with perennial AR, comparing the high-IgE (H-IgE; total serum IgE ≥200 IU/mL) and low-IgE (L-IgE; total serum IgE <200 IU/mL) groups. We measured the percentage of Breg cells and expression of CD1d, CD80 and CD86 using flow cytometry after the stimulation of B cells with CHF treatment. We also investigated the effects of mixed CHFs on cytokine expression by co-culturing Breg cells with CD4 Results: Forty-nine perennial AR patients enrolled, divided into H-IgE and L-IgE groups. Eight patients withdrew and the remaining 41 patients were included in the final analysis. Mixed CHF treatment elevated Breg cell percentages and their surface marker levels, leading to alterations in the cytokine spectra within the co-culture system of Breg cells and T cells from perennial AR patients in the H-IgE group. Conclusion: The results revealed that mixed CHFs exerted immunomodulatory mechanisms through the Breg cells to inhibit allergic reactions in the H-IgE group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.